Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Allergic bronchopulmonary aspergillosis (ABPA) is a rare immunologic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus, clinically manifesting with poorly controlled asthma and recurrent pulmonary infiltrates.
Features include: Abnormality of the immune system.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Immune system | 1 | Abnormality of the immune system |
Biomarker and diagnostic research for allergic bronchopulmonary aspergillosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
14 clinical trials registered, 10 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE3, 2 PHASE2, 2 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07362693](https://clinicaltrials.gov/study/NCT07362693) |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 4:05 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA |
— |
Qianfoshan Hospital |
RECRUITING |
[NCT07040332](https://clinicaltrials.gov/study/NCT07040332) | Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis | — | Qianfoshan Hospital | RECRUITING |
[NCT07493629](https://clinicaltrials.gov/study/NCT07493629) | Immune Status and Disease Control of Inflammatory Airway Diseases | — | First Affiliated Hospital of Ningbo University | RECRUITING |
[NCT05444946](https://clinicaltrials.gov/study/NCT05444946) | Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome | NA | Post Graduate Institute of Medical Education and Research, Chandigarh | RECRUITING |
[NCT07530770](https://clinicaltrials.gov/study/NCT07530770) | Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis | — | Qianfoshan Hospital | RECRUITING |
301 publications have been identified in PubMed for allergic bronchopulmonary aspergillosis. Kisho has analyzed 223 by research type. Research spans Case Report / Case Series (28%), Review / Meta-Analysis (27%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 62 | 28% |
Research summaries | 60 | 27% |
Disease patterns and progression | 32 | 14% |
Laboratory research | 20 | 9% |
Testing and diagnosis research | 17 | 8% |
Clinical study results | 14 | 6% |
Other research | 12 | 5% |
New treatment approaches | 6 | 3% |
Zeng XN (2026). [PMID: 41766159](https://pubmed.ncbi.nlm.nih.gov/41766159/). *Zhongguo Dang Dai Er Ke Za Zhi*. [Case Report / Case Series]
Allergy Committee of Chinese Association of Integrative Medicine (2026). [PMID: 42103676](https://pubmed.ncbi.nlm.nih.gov/42103676/). *Zhonghua Yi Xue Za Zhi*. [Review / Meta-Analysis]
Falcon RMG (2026). [PMID: 42133179](https://pubmed.ncbi.nlm.nih.gov/42133179/). *Mol Biol Rep*. [Review / Meta-Analysis]
Bautista J (2026). [PMID: 41593454](https://pubmed.ncbi.nlm.nih.gov/41593454/). *Current opinion in infectious diseases*. [Basic Science / Preclinical]
Wahab F (2026). [PMID: 42099257](https://pubmed.ncbi.nlm.nih.gov/42099257/). *Monaldi Arch Chest Dis*. [Diagnostic / Biomarker]
Saxena P (2026). [PMID: 41835114](https://pubmed.ncbi.nlm.nih.gov/41835114/). *Journal of inflammation research*. [Epidemiology / Natural History]
Li J (2026). [PMID: 42108177](https://pubmed.ncbi.nlm.nih.gov/42108177/). *Zhonghua Jie He He Hu Xi Za Zhi*. [Diagnostic / Biomarker]
Jenks JD (2026). [PMID: 29489184](https://pubmed.ncbi.nlm.nih.gov/29489184/). *Unknown Journal*. [Review / Meta-Analysis]
Lv J (2026). [PMID: 41496036](https://pubmed.ncbi.nlm.nih.gov/41496036/). *Medicine (Baltimore)*. [Case Report / Case Series]
Pavlovic F (2026). [PMID: 42095215](https://pubmed.ncbi.nlm.nih.gov/42095215/). *Open Forum Infect Dis*. [Review / Meta-Analysis]
AI-curated news mentioning allergic bronchopulmonary aspergillosis
Updated Jul 31, 2026
A Danish population-based case-control study investigates the association between inhaled and oral corticosteroid use and the risk of pulmonary aspergillosis. The findings contribute to understanding the potential risks associated with corticosteroid therapies in patients.
A case report details pulmonary aspergillosis complicated by recurrent pneumothorax in a patient with HIV. This study highlights the complexities of managing co-infections in immunocompromised individuals.
A case report highlights the complications of immune checkpoint inhibitor-associated pneumonia in a patient with chronic obstructive pulmonary disease, leading to invasive pulmonary aspergillosis. This underscores the need for careful monitoring in patients receiving these therapies.